Sample Size Based on Pharmacodynamic endpoints [Power / Sample Size]

posted by nobody – 2019-04-05 08:37  – Posting: # 20124
Views: 909

» The fact that it is also a royal waste of money is of course only secondary.

Full-blown development mode. Accept it. Tell the sponsor you can't do the trial, if you are not qualified for PD-endpoint testing.

Kindest regards, nobody

Complete thread:

Activity
 Mix view
Bioequivalence and Bioavailability Forum |  Admin contact
19,883 posts in 4,214 threads, 1,365 registered users;
online 13 (0 registered, 13 guests [including 5 identified bots]).
Forum time (Europe/Vienna): 18:24 CEST

Competence, like truth, beauty and contact lenses,
is in the eye of the beholder.    Laurence J. Peter

The BIOEQUIVALENCE / BIOAVAILABILITY FORUM is hosted by
BEBAC Ing. Helmut Schütz
HTML5